JPMorgan analyst Eric Joseph downgraded Rocket Pharmaceuticals (RCKT) to Neutral from Overweight with a price target of $7, down from $44, following the clinical hold announced on lead program RP-A501 for Danon Disease. While the firm says it came away from the company’s “transparent detailing” of the sequence of events surrounding the capillary leak syndrome and eventual death of a patient in the study “incrementally sanguine about the path forward,” it continues to think the clinical hold setback could result in a more conservative regulatory bar for approval, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals price target lowered to $19 from $51 at Scotiabank
- Broadcom, Arista Networks initiated: Wall Street’s top analyst calls
- Goldman downgrades Rocket to Sell on ‘surprising and concerning’ update
- Rocket Pharmaceuticals downgraded to Sell from Neutral at Goldman Sachs
- Rocket Pharmaceuticals: Buy Rating Affirmed Amid Strategic Adjustments and Financial Resilience
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue